Liminal BioSciences
Liminal BioSciences is a Canadian development-stage biopharmaceutical company focused on small-molecule drugs that modulate G protein-coupled receptor pathways.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Liminal BioSciences is a Canadian biopharmaceutical company whose research activities center on discovering and developing small-molecule therapeutics that act on G protein-coupled receptors, commonly abbreviated as GPCRs. The company traces its origins to commercial research spun out of work at the University of Cambridge on affinity chromatography. Pierre Laurin, whose research helped provide the scientific foundation for the business, founded the company in 1988. It was incorporated under the Canada Business Corporations Act on October 14, 1994, initially using the name Innovon Life Sciences Holdings Limited. The business later adopted the name Prometic Life Sciences Inc. on May 19, 1998. During its public-company period, Prometic pursued biotechnology and pharmaceutical development activities and expanded through corporate transactions, including the announced acquisition of Telesta Therapeutics in August 2016. The company's common shares began trading on the Toronto Stock Exchange in July 1998 under the symbol PLI. After a strategic reorientation, the company changed its corporate identity to Liminal BioSciences Inc. on October 3, 2019. Its shares began trading under the symbol LMNL on the Toronto Stock Exchange in October 2019 and on the Nasdaq Global Market in November of the same year. Liminal's later operating model focused on an integrated discovery platform combining medicinal chemistry, biology, and in-vivo research. Its scientific objective was to identify proprietary small molecules that could selectively modulate GPCR pathways involved in metabolic, inflammatory, and fibrotic diseases. GPCRs are cell-surface receptors that span the membrane seven times and are important drug targets because they can be reached by many types of therapeutic molecules and participate in signaling processes across numerous organ systems. Depending on the receptor and disease mechanism, a program may seek to activate a receptor with an agonist or block signaling with an antagonist. The company's priority pipeline described three principal programs. LMNL6511 was selected as the lead clinical-development candidate and was characterized as a selective antagonist of GPR84, a receptor associated with inflammatory biology. The company expected to begin a Phase 1 study during the second half of 2023. Two additional programs remained preclinical: antagonists directed at OXER1 and agonists directed at FFAR1, also known as GPR40. These programs were intended to support potential treatments for diseases with substantial unmet medical need, particularly in metabolic, inflammatory, and fibrotic indications. Liminal experienced significant financial and capital-market pressure during the late Prometic period. Its share price reportedly fell sharply from early 2018 into early 2019, and the company sought permission from the Toronto Stock Exchange to proceed with certain measures without a shareholder vote, citing financial hardship. The company nevertheless obtained shareholder approval for its name change in October 2019. It voluntarily delisted from the Toronto Stock Exchange in August 2020 while continuing to trade on Nasdaq for a period. In September 2023, Thomvest Asset Management took the company private, after which Liminal was delisted from Nasdaq. It is therefore best understood as a private, development-stage biotechnology business rather than a currently listed public issuer.
History
Liminal BioSciences originated in research associated with affinity chromatography at the University of Cambridge. Pierre Laurin founded the commercial venture in 1988, building on research that formed the scientific basis for the company's early activities. The enterprise was subsequently incorporated in Canada on October 14, 1994 under the Canada Business Corporations Act as Innovon Life Sciences Holdings Limited. The company adopted the name Prometic Life Sciences Inc. on May 19, 1998. It became a publicly traded company that year, with its common shares beginning to trade on the Toronto Stock Exchange on July 28 under the symbol PLI. Prometic used the public-company structure to pursue biotechnology and pharmaceutical opportunities, including expansion through acquisitions. In August 2016, it announced the acquisition of Telesta Therapeutics, a transaction that broadened the scope of its corporate and development activities. During the late 2010s, Prometic faced substantial financial and market challenges. Its share price declined sharply between early 2018 and early 2019. The company sought authorization from the Toronto Stock Exchange to proceed without a shareholder vote in circumstances it attributed to financial hardship. These pressures formed part of the background to a broader corporate restructuring and repositioning. Shareholders voted on the company's proposed name change in October 2019. On October 3, 2019, Prometic became Liminal BioSciences Inc. The company's TSX trading symbol changed to LMNL, and its shares began trading on Nasdaq's Global Market under the same symbol on November 18, 2019. Liminal later voluntarily delisted from the TSX on August 5, 2020. Its remaining public-market presence continued on Nasdaq until the company was taken private. As Liminal BioSciences, the company concentrated on small-molecule drug discovery directed at seven-transmembrane GPCRs. Its discovery platform combined chemistry and biology capabilities with in-vivo research intended to test the efficacy of preclinical candidates in animal models. The therapeutic strategy focused on receptors implicated in metabolic, inflammatory, and fibrotic disorders. The company described GPCRs as attractive targets because they are located at the cell surface, are accessible to different drug modalities, and regulate physiological processes across many organ systems. The later pipeline consisted of three principal programs. LMNL6511, a selective antagonist of GPR84, was the candidate chosen for clinical development, with a Phase 1 trial expected to start in the second half of 2023. The company also maintained preclinical programs involving OXER1 antagonists and FFAR1/GPR40 agonists. These assets reflected a strategy of developing proprietary receptor modulators for conditions characterized by significant unmet medical need. In September 2023, Thomvest Asset Management Ltd. took Liminal BioSciences private. The transaction ended the company's Nasdaq listing and marked its transition from a publicly traded biotechnology issuer to a privately held development-stage biopharmaceutical company.
- 2023
Taken private
[1]Thomvest Asset Management took the company private, resulting in its delisting from Nasdaq.
- 2020
TSX delisting
[1]Liminal voluntarily delisted its common shares from the Toronto Stock Exchange on August 5.
- 2019
Rebranding to Liminal BioSciences
[1]The company adopted the Liminal BioSciences name on October 3 and used LMNL as its trading symbol. It began Nasdaq Global Market trading later that year.
- 2016
Telesta Therapeutics acquisition announced
[1]Prometic announced the acquisition of Telesta Therapeutics in August, expanding its corporate development activities.
- 1998
Prometic name adopted and TSX listing begins
[1]The company changed its name to Prometic Life Sciences Inc. and its common shares began trading on the Toronto Stock Exchange under PLI.
- 1994
Canadian incorporation
[1]The company was incorporated on October 14 under the Canada Business Corporations Act as Innovon Life Sciences Holdings Limited.
- 1988
Company founded from Cambridge-affiliated research
[1]Pierre Laurin founded the business as a commercial spin-off of research on affinity chromatography associated with the University of Cambridge.
Products and positioning
A science-led, development-stage biotechnology company focused on proprietary small-molecule modulation of GPCR pathways for metabolic, inflammatory, and fibrotic diseases.
Clinical-stage small-molecule drug candidate
LMNL6511
LMNL6511 is a selective antagonist of the GPR84 receptor. Liminal selected it as its lead candidate for clinical development and expected to initiate a Phase 1 clinical trial in the second half of 2023. The program reflects the company's strategy of using small molecules to modulate GPCR pathways associated with inflammatory disease biology.
Preclinical GPCR drug discovery program
OXER1 antagonist program
This program sought to identify small-molecule antagonists of OXER1, a GPCR target included in Liminal's discovery portfolio. The program was at the preclinical stage and formed part of the company's effort to build a pipeline spanning inflammatory and fibrotic disease mechanisms.
Preclinical GPCR drug discovery program
FFAR1/GPR40 agonist program
The FFAR1, or GPR40, program focused on discovering agonists of a receptor associated with metabolic signaling. It was one of Liminal's priority preclinical programs and was intended to support the development of small-molecule therapies for metabolic disease and related unmet medical needs.
Brand decisions
2023
Going-private transaction with Thomvest Asset ManagementM&ABackground
After operating as a public biotechnology company, Liminal entered a transaction intended to move the business into private ownership.
Action taken
Thomvest Asset Management Ltd. took Liminal BioSciences private in September 2023.
Aftermath
Liminal was delisted from Nasdaq and ceased to be a publicly traded company.
2020
Voluntary withdrawal from the Toronto Stock ExchangeStrategyBackground
Liminal maintained a Nasdaq listing after its 2019 rebranding but decided to discontinue its TSX listing.
Action taken
The company voluntarily delisted its common shares from the TSX on August 5, 2020.
Aftermath
The company continued as a Nasdaq-listed issuer until it was subsequently taken private.
2019
Corporate rebranding from Prometic to LiminalStrategyBackground
Following a period of financial and market pressure, the company sought to reposition its corporate identity and public-market profile.
Action taken
The company changed its name from Prometic Life Sciences Inc. to Liminal BioSciences Inc. and adopted LMNL as its trading symbol.
Aftermath
The rebranding was followed by Nasdaq trading under LMNL, while the company continued developing a GPCR-focused small-molecule pipeline.
Recent events
Liminal BioSciences closes sale of plasma-derived therapeutics manufacturing subsidiary[2]
Reported:
Liminal BioSciences announced that it had closed the divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion. The sale consideration for Prometic Bioproduction was USD 5 million, subject to adjustments.
Liminal BioSciences announces plasma business divestment agreement with Kedrion[3]
Reported:
Liminal BioSciences reported that it had entered into a definitive share purchase agreement for the divestment of its plasma collection centers and an option agreement for the divestment of its Ryplazim-related assets with Kedrion. The proposed transaction was not reported as completed.
Liminal BioSciences reported fourth-quarter and 2020 results[4]
Reported:
Liminal BioSciences reported financial results for the fourth quarter and year ended December 31, 2020.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/liminal-biosciences · Editorial policy · How profiles are compiled